Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118066 · ClinicalTrials.gov registry record · Phase 2
Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00118066 is a Phase 2 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 12 participants.
The verdict
NCT00118066, a Phase 2 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of calcitriol may prevent prostate cancer. It is not yet known whether calcitriol is more effective than observation in preventing prostate cancer. PURPOSE: This randomized phase II trial is studying how well calcitriol works in preventing prostate cancer in patients with prostatic intraepithelial neoplasia.
Interventions
- DIETARY_SUPPLEMENT calcitriol
- PROCEDURE observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-05 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118066
The ClinicalTrials.gov registry entry for NCT00118066 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which calcitriol is the first listed.
NCT00118066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118066 about?
NCT00118066 is a clinical study titled "Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of calcitriol may prevent prostate cancer. It is not yet known whether calcitriol is more effective than observation in preventing prostate cancer. PURPOSE: This randomized phase II ...
What is the current status of trial NCT00118066?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2004-05. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00118066?
The interventions under investigation include: calcitriol (DIETARY_SUPPLEMENT), observation (PROCEDURE).
Who is sponsoring clinical trial NCT00118066?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.